Pharmacokinetics of penciclovir after oral administration of its prodrug famciclovir to horses

Journal of Veterinary Medical Science

Volumn 72, Issue 3, 2010, Pages 357-361

  Tsujimura, Koji ^a   Yamada, Masayuki ^b   Nagata, Shun Ichi ^b   Yamanaka, Takashi ^a   Nemoto, Manabu ^a   Kondo, Takashi ^a   Kurosawa, Masahiko ^b   Matsumura, Tomio ^a  

^a EQUINE RESEARCH INSTITUTE   (Japan)

^b LABORATORY OF RACING CHEMISTRY   (Japan)

Author keywords

Equine; Famciclovir; Penciclovir; Pharmacokinetics

Indexed keywords

2 AMINOPURINE; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; FAMCICLOVIR; PENCICLOVIR;

ANIMAL; ANIMAL DISEASE; AREA UNDER THE CURVE; ARTICLE; BLOOD; DRUG EFFECT; EQUINE HERPES VIRUS; HALF LIFE TIME; HERPES VIRUS INFECTION; HORSE; HORSE DISEASE; ORAL DRUG ADMINISTRATION; VIROLOGY;

2-AMINOPURINE; ACYCLOVIR; ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; HALF-LIFE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HORSE DISEASES; HORSES;

EQUIDAE;

EID: 77950346394     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.09-0350     Document Type: Article

References (36)

1. Allen, G. P., Kydd, J. H., Slater, J. D. and Smith, K. C. 2004. Equid herpesvirus 1 and equid herpesvirus 4 infections. pp. 829-859. In: Infectious Diseases of Livestock (Coetzer, J. A. W. and Tustin, R. C. eds.), Oxford University Press, Cape Town.
2. Bacon, T. H. and Howard, B. A. 1996. Further characterization of the potent and prolonged inhibition of herpes simplex virus replication in human cell lines by penciclovir. Antiviral Chem. Chemother. 7: 128-137.
3. Bacon, T. H., Gilbart, J., Howard, B. A. and Standring-Cox, R. 1996. Inhibition of varicella-zoster virus by penciclovir in cell culture and mechanism of action. Antiviral Chem. Chemother. 7: 71-78.
4. Bentz, B. G., Maxwell, L. K., Erkert, R. S., Royer, C. M., Davis, M. S., MacAllister, C. G. and Clarke, C. R. 2006. Pharmacokinetics of acyclovir after single intravenous and oral administration to adult horses. J. Vet. Intern. Med. 20: 589-594.
5. Boyd, M. R., Boon, R., Fowles, S. E., Pagano, K., Sutton, D., Vere Hodge, R. A. and Zussman, B. D. 1988. Some biological properties of BRL 42810, a well absorbed oral prodrug of the antiherpesvirus agent BRL 39123. Antiviral Res. 9: 146.
6. Boyd, M. R., Bacon, T. H. and Sutton, D. 1988. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals. Antimicrob. Agents Chemother. 32: 358-363.
7. Borchers, K., Thein, R. and Sterner-Kock, A. 2006. Pathogenesis of equine herpesvirus-associated neurological disease: a revised explanation. Equine Vet. J. 38: 283-287.
8. Cardwell, J., Smith, K., Newton, R., Blunden, T., Bestbier, M. and Whitwell, K. 2003. EHV paralytic disease in the south of England. Vet. Rec. 152: 441-442.
9. de la Fuente, R., Awan, A. R. and Field, H. J. 1992. The acyclic nucleoside analogue penciclovir is a potent inhibitor of equine herpesvirus type 1 (EHV-1) in tissue culture and in a murine model. Antiviral Res. 18: 77-89.
10. Earnshaw, D. L., Bacon, T. H., Darlison, S. J., Edmonds, K., Perkins, R. M. and Vere Hodge, R. A. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob. Agents Chemother. 36: 2747-2757.
11. Filer, C. W., Ramji, J. V., Allen, G. D., Brown, T. A., Fowles, S. E., Hollis, F. J. and Mort, E. E. 1995. Metabolic and pharmacokinetic studies following oral administration of famciclovir to the rat and dog. Xenobiotica 25: 477-490.
12. Filer, C. W., Allen, G. D., Brown, T. A., Fowles, S. E., Hollis, F. J., Mort, E. E., Prince, W. T. and Ramji, J. V. 1994. Metabolic and pharmacokinetic studies following oral administration of 14C-famciclovir to healthy subjects. Xenobiotica 24: 357-368.
13. Friday, P. A., Scarratt, W. K., Elvinger, F., Timoney, P. J. and Bonda, A. 2000. Ataxia and paresis with equine herpesvirus type 1 infection in a herd of riding school horses. J. Vet. Intern. Med. 14: 197-201.
14. Garré, B., Gryspeerdt, A., Croubels, S., De Backer, P. and Nauwynck, H. 2009. Evaluation of orally administered valacyclovir in experimentally EHV1-infected ponies. Vet. Microbiol. 135: 214-221.
15. Garré, B., Shebany, K., Gryspeerdt, A., Baert, K., van der Meulen, K., Nauwynck, H., Deprez, P., De Backer, P. and Croubels, S. 2007. Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses. Antimicrob. Agents Chemother. 51: 4308-4314.
16. Garré, B., van der Meulen, K., Nugent, J., Neyts, J., Croubels, S., De Backer, P. and Nauwynck, H. 2007. In vitro susceptibility of six isolates of equine herpesvirus 1 to acyclovir, ganciclovir, cidofovir, adefovir, PMEDAP and foscarnet. Vet. Microbiol. 122: 43-51.
17. Gilkerson, J. R. and Barrett, E. J. 2008. Equine herpesvirus neurological disease. Equine Vet. J. 40: 102-103.
18. Goehring, L. S., van Winden, S. C., van Maanen, C. and Sloet van Oldruitenborgh-Oosterbaan, M. M. 2006. Equine herpesvirus type 1-associated myeloencephalopathy in The Netherlands: a four-year retrospective study (1999-2003). J. Vet. Intern. Med. 20: 601-607.
19. Goehring, L. S., van Maanen, C. and Sloet van Oldruitenborgh-Oosterbaan, M. M. 2005. Neurological syndromes among horses in The Netherlands. A 5 year retrospective survey (1999-2004). Vet. Q. 27: 11-20.
20. Henninger, R. W., Reed, S. M., Saville, W. J., Allen, G. P., Hass, G. F., Kohn, C. W. and Sofaly, C. 2007. Outbreak of neurologic disease caused by equine herpesvirus-1 at a university equestrian center. J. Vet. Intern. Med. 21: 157-165.
21. Maggs, D. J. and Clarke, H. E. 2004. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am. J. Vet. Res. 65: 399-403.
22. Malik, R., Lessels, N. S., Webb, S., Meek, M., Graham, P. G., Vitale, C., Norris, J. M. and Power, H. 2009. Treatment of feline herpesvirus-1 associated disease in cats with famciclovir and related drugs. J. Feline Med. Surg. 11: 40-48.
23. Maxwell, L. K., Bentz, B. G., Bourne, D. W. and Erkert, R. S. 2008. Pharmacokinetics of valacyclovir in the adult horse. J. Vet. Pharmacol. Ther. 31: 312-320.
24. Pue, M. A. and Benet, L. Z. 1993. Pharmacokinetics of famciclovir in man. Antiviral Chem. Chemother. 4 (Suppl. 1): 47-55.
25. Pue, M. A., Pratt, S. K., Fairless, A. J., Fowles, S., Laroche, J., Georgiou, P. and Prince, W. 1994. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J. Antimicrob. Chemother. 33: 119-127.
26. Schenkel, F., Rudaz, S., Daali, Y., Oestreicher, M. K., Veuthey, J. L. and Dayer, P. 2005. Development and validation of a new reversed-phase ion pairing liquid chromatographic method with fluorescence detection for penciclovir analysis in plasma and aqueous humor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 826: 1-7.
27. Simpson, D. and Lyseng-Williamson, K. A. 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 66: 2397-2416.
28. Sutton, D. and Boyd, M. R. 1993. Comparative activity of penciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16. Antimicrob. Agents Chemother. 37: 642-645.
29. Tod, M., Lokiec, F., Bidault, R., De Bony, F., Petitjean, O. and Aujard, Y. 2001. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob. Agents Chemother. 45: 150-157.
30. Thomasy, S. M., Maggs, D. J., Moulin, N. K. and Stanley, S. D. 2007. Pharmacokinetics and safety of penciclovir following oral administration of famciclovir to cats. Am. J. Vet. Res. 68: 1252-1258.
31. Vere Hodge, R. A. 1993. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 4 (Suppl. 1): 67-84.
32. Vere Hodge, R. A. and Cheng, Y. -C. 1993. The mode of action of penciclovir. Antiviral Chem. Chemother. 4 (Suppl. 1): 13-24.
33. Vere Hodge, R. A. and Perkins, R. M. 1989. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob. Agents Chemother. 33: 223-229.
34. Vere Hodge, R. A., Sutton, D., Boyd, M. R., Harnden, M. R. and Jarvest, R. L. 1989. Selection of an oral prodrug (BRL 42810; famciclovir) for the antiherpesvirus agent BRL 39123 [9-(4-hydroxy-3-hydroxymethylbut-l-yl)guanine; penciclovir]. Antimicrob. Agents Chemother. 33: 1765-1773.
35. Wilkins, P. A., Papich, M. and Sweeney, R. D. 2005. Pharmacokinetics of acyclovir in adult horses. J. Vet. Emerg. Crit. Care 15: 174-178.
36. Wilkins, P. A., Del Piero, F., de Lahunta, A., Gleed, R. D. and Dubovi, E. J. 1998. Paralytic equine herpes virus: 1978-1997. pp. 596-597. In: Equine Infectious Diseases VIII (Wernery, U., Wade, J. F., Mumford, J. A. and Kaaden, O. R. eds.), R&W Publisher, Newmarket.